Slingshot members are tracking this event:

Gilead (GILD) Expects Phase 3 Data Evaluating Bictegravir Single-Tablet Regimen (B/F/TAF) in Combination with Tenofovir Alafenamide (TAF) and Emtricitabine (FTC) for the Treatment of HIV-1 infection in Mid 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bictegravir, Tenofovir Alafenamide, Emtricitabine, B/f/taf, Hiv-1 Infection